Brought to you by
ECR 2018 / C-3001
Transarterial Chemo-embolisation with degradable starch microspheres(DSM-TACE) in intermediate/advanced HCC patients dismissing or inelegible for Sorafenib
Congress: ECR 2018
Poster No.: C-3001
Type: Scientific Exhibit
Keywords: Oncology, Interventional non-vascular, Liver, Catheter arteriography, Percutaneous, CT, Chemoembolisation, Chemotherapy, Treatment effects, Cancer
Authors: F. Carchesio, R. Iezzi, A. Posa, M. Pompili, A. Gasbarrini, R. Manfredi; Rome/IT




  1. Transarterial chemoembolization with degradable starch microspheres (DSM-TACE): an alternative option for advanced HCC patients? Preliminary results ; R. Iezzi, M. Pompili, M. Nestola, M. Siciliano, E. Annicchiarico, M.A. Zocco, E. Rinninella, A. Posa, G.E.M. Antonuccio, A. Gasbarrini, L. Bonomo, and Hepatocatt Study Group; Eur Rev Med Pharmacol Sci 2016; 20 (13): 2872-2877
  2. Interventional treatment for unresectable hepatocellular carcinoma; Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita S; World J Gastroenterol 2014; 20: 13453-13465
  3. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Josep M. Llovet, Concepció Brú, Jordi Bruix; Semin Liver Dis 1999; 19: 329-338.
  4. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C; Hepatology 2010; 51: 1274-1283.
  5. Sorafenib in advanced hepatocellular carcinoma; Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators StudyGroup.; N Engl J Med. 2008 24;359(4):378-90
  6. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Lancet Oncol. 2009 Jan;10(1):25-34. 
  7. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? BiolatoM., Marrone G, Racco S, Di Stasi C, Miele L., Gasbarrini G., Landolfi R., Grieco A.; Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):356-62
  8. Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study; Wiggermann P, Wohlgemuth WA, Heibl M, Vasilj A, Loss M, Schreyer AG, Stroszczynski C, Jung EM; Clin Hemorheol Microcirc. 2013;
  9. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma; Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.; J Vasc Interv Radiol. 2014
  10. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial; Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I.; J Gastroenterol. 2011 Mar;46(3):359-66
  11. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; Lencioni R, Llovet JM; Semin Liver Dis 2010; 30: 52-60
  12. Management of hepatocellular carcinoma; BuixJ, Sherman M, Prectice Guidelines Committee, American Association for the Study of Liver Disease; Hepatology 2005; 42: 1208-1236 
  13. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. J Hepatol. 2012;56(4):908-43
  14. Molecular targeted therapies in hepatocellular carcinoma. Llovet JM, Bruix J; Hepatology 2008; 48: 1312-1327.
  15. Review article: the management of hepatocellular carcinoma; abrera R., Nelson DR;  Aliment Pharmacol Ther 2010; 31: 461-476
  16. American Association for the Study of Liver Diseases. Management of hepato- cellular carcinoma: an update; Bruix J, Sherman M.; Hepatology 2011; 53: 1020-1022. 
  17. Management of hepatocellular carcinoma: beyond sorafenib; Chan SL, Mok T, Ma BB; Curr Oncol Rep 2012; 14: 257-266.
  18. Updates in the management of hepatocellular carcinoma; Wong R, Frenette C.; Gastroenterol Hepatol 2011; 7: 16-24 
  19. Drug therapy for ad- vanced-stage liver cancer, Peck-Radosavlevic; Liver Cancer 2014; 3: 125-131. 
POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more